6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation

Author(s): Ondrej Benek, Lukas Hroch, Laura Aitken, Rafael Dolezal, Patrick Guest, Marketa Benkova, Ondrej Soukup, Karel Musil, Kamil Kuca, Terry K. Smith, Frank Gunn-Moore*, Kamil Musilek*

Journal Name: Medicinal Chemistry

Volume 13 , Issue 4 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The mitochondrial enzyme amyloid beta-binding alcohol dehydrogenase (ABAD) also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) has been connected with the pathogenesis of Alzheimer’s disease (AD). ABAD/17β-HSD10 is a binding site for the amyloid-beta peptide (Aβ) inside the mitochondrial matrix where it exacerbates Aβtoxicity. Interaction between these two proteins triggers a series of events leading to mitochondrial dysfunction as seen in AD.

Methods: As ABAD’s enzymatic activity is required for mediating Aβ toxicity, its inhibition presents a promising strategy for AD treatment. In this study, a series of new benzothiazolylurea analogues have been prepared and evaluated in vitro for their potency to inhibit ABAD/17β-HSD10 enzymatic activity. The most potent compounds have also been tested for their cytotoxic properties and their ability to permeate through blood-brain barrier has been predicted. To explain the structureactivity relationship QSAR and pharmacophore studies have been performed.

Results and Conclusion: Compound 12 was identified being the most promising hit compound with good inhibitory activity (IC50 = 3.06 ± 0.40 µ M) and acceptable cytotoxicity profile comparable to the parent compound of frentizole. The satisfactory physical-chemical properties suggesting its capability to permeate through BBB make compound 12 a novel lead structure for further development and biological assessment.

Keywords: 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), alzheimer’s disease, amyloid-beta binding alcohol dehydrogenase (ABAD), chemical synthesis, enzyme inhibition, frentizole, pharmacophore modelling, QSAR.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 09 January, 2017
Page: [345 - 358]
Pages: 14
DOI: 10.2174/1573406413666170109142725
Price: $65

Article Metrics

PDF: 41
PRC: 1